AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 115 filers reported holding AKERO THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,952,388 | -91.0% | 38,600 | -98.3% | 0.01% | -93.5% |
| Q2 2022 | $21,735,000 | -17.1% | 2,300,000 | +24.5% | 0.09% | -11.5% |
| Q1 2022 | $26,209,000 | -29.5% | 1,847,000 | +5.0% | 0.10% | -30.2% |
| Q4 2021 | $37,192,000 | +19.0% | 1,758,501 | +25.8% | 0.15% | +8.8% |
| Q3 2021 | $31,254,000 | +5.7% | 1,398,400 | +17.3% | 0.14% | +3.0% |
| Q2 2021 | $29,566,000 | +101.2% | 1,191,700 | +135.3% | 0.13% | +92.8% |
| Q1 2021 | $14,693,000 | -19.2% | 506,497 | -28.2% | 0.07% | -22.5% |
| Q4 2020 | $18,189,000 | +312.7% | 705,000 | +392.5% | 0.09% | +287.0% |
| Q3 2020 | $4,407,000 | -60.3% | 143,139 | -67.8% | 0.02% | -68.1% |
| Q2 2020 | $11,090,000 | -27.9% | 445,032 | -38.6% | 0.07% | -42.4% |
| Q1 2020 | $15,375,000 | +206.1% | 725,245 | +220.5% | 0.12% | +380.8% |
| Q4 2019 | $5,023,000 | +107.0% | 226,300 | +112.1% | 0.03% | +73.3% |
| Q3 2019 | $2,427,000 | +322.1% | 106,700 | +255.7% | 0.02% | +400.0% |
| Q2 2019 | $575,000 | – | 30,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 3,271,829 | $179,296 | 57.03% |
| Redmile Group, LLC | 2,632,912 | $144,283,578 | 5.90% |
| Avidity Partners Management LP | 3,825,000 | $209,610,000 | 4.54% |
| COMMODORE CAPITAL LP | 537,076 | $29,432 | 4.44% |
| Atlas Venture Life Science Advisors, LLC | 594,251 | $32,564,955 | 3.92% |
| Paradigm Biocapital Advisors LP | 604,544 | $33,129,011 | 3.89% |
| Yiheng Capital Management, L.P. | 1,468,905 | $80,495,994 | 3.56% |
| Altium Capital Management LP | 125,000 | $6,850,000 | 3.48% |
| Tri Locum Partners LP | 128,851 | $7,061,000 | 2.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 172,100 | $9,431,080 | 2.70% |